<DOC>
	<DOC>NCT00609921</DOC>
	<brief_summary>This is a Phase 1, open label, dose escalation study of ARQ 197 in patients with advanced/recurrent solid tumors. The purpose of this study is to determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.</brief_summary>
	<brief_title>A Phase 1 Study of ARQ 197 in Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Patients who did not respond or are refractory to available therapy or for whom no standard effective systemic therapy exists. Karnofsky performance status (KPS) â‰¥ 70%, or Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 Patients with adequate organ function Anticancer chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks prior to the first dose of ARQ 197 Known symptomatic brain metastases Pregnant or breastfeeding Uncontrolled intercurrent illness</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>